Immuneering Corporation (IMRX)
Nasdaq: IMRX · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2019
Filings
159 filings since 2017 beside 166 insider forms · and emerging growth company · read from EDGAR on Nov 13, 2026Due next and emerging growth company
10-K
Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends.
by Mar 31, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end.
by May 15, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 29 days after the quarter ended. The proxy statement was last filed Apr 20, 2026.
Filings a yearinsider forms included
11575138597444
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 5 times in the last 36 months, the newest Nov 9, 2026.SEC letters: 4 in the last 36 months, the newest Sep 4, 2025.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Sep 25, 2025
8-K items 1.01, 8.01, 9.01
Major agreement signed; Other event · Current report
Sep 24, 2025
Sep 24, 2025
8-K items 1.01, 3.02, 8.01, 9.01
Major agreement signed; Shares sold without registration; Other event · Current report
Aug 25, 2025
8-K items 1.01, 3.02, 8.01, 9.01
Major agreement signed; Shares sold without registration; Other event · Current report
Aug 21, 2025
40 of 159 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.